Adherence to treatment in patients with psoriasis.

A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open (2013) 3.38

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes (2013) 0.98

Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med (2010) 0.90

'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Fam Pract (2013) 0.90

Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study). Ann Dermatol (2013) 0.84

Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res (2014) 0.80

Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant. J Dermatol Nurses Assoc (2016) 0.78

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence (2016) 0.78

Microsphere technology: hype or help? J Clin Aesthet Dermatol (2011) 0.76

Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics (2007) 0.75

The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits (2016) 0.75

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis. Dermatol Ther (Heidelb) (2016) 0.75

[Adherence to treatment in chronic dermatosis: about 200 cases]. Pan Afr Med J (2015) 0.75

Myths and Facts about Vitiligo: An Epidemiological Study. Indian J Pharm Sci (2015) 0.75

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol (2009) 4.12

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10

Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut (2005) 2.36

Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]. Br J Dermatol (2009) 2.25

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72

Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol (2005) 1.67

Pain drawings in the assessment of nerve root compression: a comparative study with lumbar spine magnetic resonance imaging. Spine (Phila Pa 1976) (1998) 1.63

Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60

Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br J Dermatol (2002) 1.59

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol (2005) 1.49

Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis (2007) 1.47

Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet (2007) 1.44

Geographical ancestry is a key determinant of epidermal morphology and dermal composition. Br J Dermatol (2014) 1.40

Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. Br J Dermatol (2014) 1.39

Making a 'point' about the safe disposal of sharps in patients on biological therapies. Br J Dermatol (2008) 1.37

Patients with psoriasis and their compliance with medication. J Am Acad Dermatol (1999) 1.28

A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol (2002) 1.27

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26

Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol (2012) 1.23

Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol (2003) 1.17

Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol (2013) 1.14

Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis (2007) 1.13

Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes Immun (2009) 1.12

The role of neuropeptides in psoriasis. Br J Dermatol (2006) 1.12

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol (2005) 1.11

The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol (2000) 1.10

Inpatient management of psoriasis: a multicentre service review to establish national admission standards. Br J Dermatol (2007) 1.10

Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res (2002) 1.09

Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev (2006) 1.09

Striae gravidarum in primiparae. Br J Dermatol (2006) 1.08

The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res (2001) 1.06

Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) (2005) 1.05

Circulating natural killer cells in psoriasis. Br J Dermatol (2003) 1.04

Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol (2004) 1.04

Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol (2006) 1.04

IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol (2003) 1.03

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol (2005) 1.03

Management of primary cicatricial alopecias: options for treatment. Br J Dermatol (2008) 1.03

The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol (2005) 1.00

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00

How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. Br J Dermatol (2009) 0.99

Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol (2002) 0.98

A new wrinkle on old skin: the role of elastic fibres in skin ageing. Int J Cosmet Sci (2010) 0.98

Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol (2012) 0.96

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol (2012) 0.95

Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol (2007) 0.95

Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol (2006) 0.94

In search of oral psoriasis. Arch Dermatol Res (2011) 0.94

Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94

Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol (2013) 0.93

Interventions for photodamaged skin. Cochrane Database Syst Rev (2005) 0.92

Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. Br J Dermatol (2005) 0.91

Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol (2009) 0.90

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol (2008) 0.90

Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther (2007) 0.89

Altered claudin expression is a feature of chronic plaque psoriasis. J Pathol (2007) 0.89

A pilot study examining mindfulness-based cognitive therapy in psoriasis. Psychol Health Med (2014) 0.89

Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin. Br J Dermatol (2004) 0.89

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol (2009) 0.88

Repair of photoaged dermal matrix by topical application of a cosmetic 'antiageing' product. Br J Dermatol (2007) 0.87

Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol (2012) 0.87

Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. Br J Dermatol (2002) 0.87

Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol (2002) 0.87

Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol (2004) 0.86

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol (2005) 0.86

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol (2006) 0.86

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol (2009) 0.86

Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol (2006) 0.85

Naevus sebaceus: a mosaic RASopathy. Clin Exp Dermatol (2014) 0.85

Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol (2006) 0.84

The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. Br J Dermatol (2014) 0.84

A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol (2011) 0.84

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol (2008) 0.83

A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scand J Rheumatol (2013) 0.83

Recent advances in cutaneous angiogenesis. Br J Dermatol (2002) 0.83

'In someone's clinic but not in mine'--clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. Br J Dermatol (2014) 0.82

Cytokine blocking agents in dermatology. Clin Exp Dermatol (2002) 0.82

Keloidal scleroderma. Clin Exp Dermatol (2003) 0.81

Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings. Clin Exp Dermatol (2003) 0.81

Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat (2003) 0.80

No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis. Clin Exp Dermatol (2011) 0.80

Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol (2014) 0.80

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol (2012) 0.80

Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. Br J Dermatol (2015) 0.80

Novel immune-based therapies for psoriasis. Br J Dermatol (2002) 0.80

A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. Br J Dermatol (2013) 0.80

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol (2010) 0.80

An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. Br J Dermatol (2013) 0.79

A temporal analysis of the central neural processing of itch. Br J Dermatol (2012) 0.79

CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. Br J Dermatol (2004) 0.79

Patients' strategies for coping with psoriasis. Clin Exp Dermatol (2002) 0.79

A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. Exp Dermatol (2003) 0.79

Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs (2011) 0.79

Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. Br J Dermatol (2010) 0.79

Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology (2005) 0.79

Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol (2008) 0.78